COX-2在非小细胞肺癌中的表达及其预后意义

Expression of COX-2 and its prognostic significance in non-small cell lung cancer

目的 探讨非小细胞肺癌组织中COX 2的表达情况及其与患者临床病理生理特征和预后的关系。方法 应用免疫组织化学S P法检测 5 2例NSCLC组织中COX 2蛋白的表达情况。结果 5 2例NSCLC组织中 2 5例 ( 4 8.1% )COX 2表达阳性。其中腺癌COX 2阳性表达率为 76.5 % ,明显高于鳞癌3 4.3 % (P <0 .0 1)。COX 2阳性表达率在T1+T2 期 ( 3 3 .3 % )显著低于T3 +T4期 ( 92 .3 % ) (P <0 .0 1) ,在临床Ⅰ +Ⅱ期 ( 2 8.1% )显著低于临床Ⅲ +Ⅳ期 ( 80 .0 % ) (P <0 .0 1)。有淋巴结转移者COX 2阳性表达率为83 .3 % ,而阴性者仅为 17.9% (P <0 .0 1)。另外 ,在生存期≤ 2年、>2但 <5年和≥ 5年三组之间COX 2阳性表达率亦有显著性差异 (P <0 .0 1)。结论 COX 2在NSCLC尤其是腺癌中呈过度表达 ,与NSCLC的侵袭性、淋巴结转移、临床分期和肺癌进展等生物学行为有密切关系。检测NSCLC组织中COX 2表达有助于预测患者预后。

Objective To investigate the expression of COX-2 and its relation to clinical pathophysiological features and prognosis in non-small cell lung cancer (NSCLC). Methods The expression of COX-2 protein was detected in 52 NSCLC tissues by immunohistochemical (S-P) method. Results The positive COX-2 expression was observed in 25 (48.1%) cases of NSCLC tissues. The positive rate of COX-2 expression was 76.5% and 34.3% in adenocarcinoma and squamous cell carcinoma respectively (P<0.01). The positive rate of COX-2 expression in T3+T4 disease (92.3%) was remarkably higher than that in stage T1+T2 (33.3%) (P<0.01). There was a remarkable difference in COX-2 expression rate between clinical stage Ⅰ+Ⅱ (28.1%) and clinical stage Ⅲ+Ⅳ (80.0%) groups (P<0.01). The positive rate of COX-2 expression was 83.3% in those with lymph node metastasis, but only 17.9% in those without lymph node metastasis (P< 0.01). In addition, there were significant differences in positive rate of COX-2 expression among patients with ≤2, >2 but <5, ≥5 years of survival span respectively (P<0.01). Conclusion Overexpression of COX-2 in NSCLC, especially in adenocarcinoma, is closely related to invasion, lymph node metastasis and clinical stage of lung cancer. It may play a role in development of NSCLC, and also may be a prognostic marker.